A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

OBJECTIVE: To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and UAE equivalent to 15–300 mg/24 h, de...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhalaf, Alaa, Klooster, Astrid, van Oeveren, Willem, Achenbach, Ulrike, Kleefstra, Nanne, Slingerland, Robbert J., Mijnhout, G. Sophie, Bilo, Henk J.G., Gans, Reinold O.B., Navis, Gerjan J., Bakker, Stephan J.L.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890365/
https://www.ncbi.nlm.nih.gov/pubmed/20413516
http://dx.doi.org/10.2337/dc09-2241
_version_ 1782182779875753984
author Alkhalaf, Alaa
Klooster, Astrid
van Oeveren, Willem
Achenbach, Ulrike
Kleefstra, Nanne
Slingerland, Robbert J.
Mijnhout, G. Sophie
Bilo, Henk J.G.
Gans, Reinold O.B.
Navis, Gerjan J.
Bakker, Stephan J.L.
author_facet Alkhalaf, Alaa
Klooster, Astrid
van Oeveren, Willem
Achenbach, Ulrike
Kleefstra, Nanne
Slingerland, Robbert J.
Mijnhout, G. Sophie
Bilo, Henk J.G.
Gans, Reinold O.B.
Navis, Gerjan J.
Bakker, Stephan J.L.
author_sort Alkhalaf, Alaa
collection PubMed
description OBJECTIVE: To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and UAE equivalent to 15–300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43). RESULTS: Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion. CONCLUSIONS: In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.
format Text
id pubmed-2890365
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-28903652011-07-01 A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy Alkhalaf, Alaa Klooster, Astrid van Oeveren, Willem Achenbach, Ulrike Kleefstra, Nanne Slingerland, Robbert J. Mijnhout, G. Sophie Bilo, Henk J.G. Gans, Reinold O.B. Navis, Gerjan J. Bakker, Stephan J.L. Diabetes Care Original Research OBJECTIVE: To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes and UAE equivalent to 15–300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43). RESULTS: Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion. CONCLUSIONS: In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status. American Diabetes Association 2010-07 2010-04-22 /pmc/articles/PMC2890365/ /pubmed/20413516 http://dx.doi.org/10.2337/dc09-2241 Text en © 2010 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details.
spellingShingle Original Research
Alkhalaf, Alaa
Klooster, Astrid
van Oeveren, Willem
Achenbach, Ulrike
Kleefstra, Nanne
Slingerland, Robbert J.
Mijnhout, G. Sophie
Bilo, Henk J.G.
Gans, Reinold O.B.
Navis, Gerjan J.
Bakker, Stephan J.L.
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
title A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
title_full A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
title_fullStr A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
title_full_unstemmed A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
title_short A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
title_sort double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890365/
https://www.ncbi.nlm.nih.gov/pubmed/20413516
http://dx.doi.org/10.2337/dc09-2241
work_keys_str_mv AT alkhalafalaa adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT kloosterastrid adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT vanoeverenwillem adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT achenbachulrike adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT kleefstrananne adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT slingerlandrobbertj adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT mijnhoutgsophie adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT bilohenkjg adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT gansreinoldob adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT navisgerjanj adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT bakkerstephanjl adoubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT alkhalafalaa doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT kloosterastrid doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT vanoeverenwillem doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT achenbachulrike doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT kleefstrananne doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT slingerlandrobbertj doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT mijnhoutgsophie doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT bilohenkjg doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT gansreinoldob doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT navisgerjanj doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy
AT bakkerstephanjl doubleblindrandomizedplacebocontrolledclinicaltrialonbenfotiaminetreatmentinpatientswithdiabeticnephropathy

Ejemplares similares